ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Saturday, November 16, 2024

10:30AM-12:30PM: Abstract Number: 0268

Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study

Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0557

What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)

SpA Including PsA – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0360

What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study

Patient Outcomes, Preferences, & Attitudes Poster I

10:30AM-12:30PM: Abstract Number: 0259

Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series

Infection-related Rheumatic Disease Poster

10:30AM-12:30AM: Abstract Number: PP08

Whispers of Resilience: Navigating Life with Rheumatism

Patient Perspectives Poster

10:30AM-12:30PM: Abstract Number: 0658

Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study

SLE – Treatment Poster I

1:00PM-2:30PM: Abstract Number: 0817

2024 Clinical Practice Guideline for the Diagnosis and Treatment of Chronic Nonbacterial Osteitis (CNO) in Adults

Abstracts: SpA Including PsA – Diagnosis, Manifestations, & Outcomes I

1:00PM-2:30PM: Abstract Number: 0782

30-Color Full Spectrum Flow Cytometry Identifies Sex Differences in the Circulating Immune Landscape of Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

1:00PM-2:30PM: Abstract Number: 0812

A Human Gut Pathobiont Drives Platelet Activation with Microparticle Release and NETosis During Lupus Nephritis Flares

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes I: Omics

1:00PM-2:30PM: Abstract Number: 0775

A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease I

1:00PM-2:30PM: Abstract Number: 0823

A Randomized, Double-Blind, Placebo-Controlled Trial of Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis with Polyangiitis

Abstracts: Vasculitis – ANCA-Associated I

1:00PM-2:30PM: Abstract Number: 0798

Acute Activation of the Rat Dorsal Root Ganglion Nociceptive Cells by the Serum of Patients Suffering from Fibromyalgia

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

1:00PM-2:30PM: Abstract Number: 0781

An Expanded Cytotoxic CD8 T Cell Population Regulated by CD155-CD226 in SSc-ILD

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

1:00PM-2:30PM: Abstract Number: 0789

An Online Trial to Assess the Efficacy and Safety of a Supplement Combination in People with Hand Osteoarthritis

Abstracts: Osteoarthritis – Clinical Trials

1:00PM-2:30PM: Abstract Number: 0797

Associations Between Discordance of Disease Activity Indices and Quantitative Sensory Testing Measures of Nociplastic Pain in Patients with Early Rheumatoid Arthritis

Abstracts: Pain in Rheumatic Disease Including Fibromyalgia

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].